#USA #San Francisco #Hagens Berman #Erasca #ERAS-0015

Investor Alert: Erasca Securities Class Action Investigation

Hagens Berman, a prominent national shareholder rights law firm, has announced its ongoing investigation into potential securities law violations concerning Erasca, Inc. (NASDAQ: ERAS). This investigation is particularly focused on allegations stemming from the company's patent litigation and patient safety risks associated with their lead oncology candidate, ERAS-0015.

Background on the Investigation

The class action lawsuit claims that Erasca knowingly provided misleading information to its investors. This included overstating the safety and efficacy of ERAS-0015, which the company touted as a revolutionary treatment in the oncology landscape. Key allegations suggest that Erasca and its executive team misrepresented the competitive advantage and security of the product's intellectual property, leading investors to suffer substantial financial losses.

The investigation specifically targets disclosures made between January 14, 2025, and April 26, 2026, where the company claimed that ERAS-0015 was a 'best-in-class' treatment for cancer. However, many investors were left in the dark about significant risks associated with the drug's trials.

Allegations of Misleading Information

The lawsuit outlines several key points indicating that Erasca misled its investors:

• - Improper Preclinical Comparisons: The lawsuit suggests that Erasca may have used flawed analyses to claim superiority over other similar treatments, specifically mentioning Revolution Medicines' RMC-6236.
• - Concealing IP Disputes: While assuring investors about the security of its intellectual property, the company neglected to disclose ongoing patent infringement concerns and potential trade secret violations.
• - Downplaying Safety Risks: Erasca reportedly celebrated safety results without adequately informing investors about dangerous incidents, including a patient death related to ERAS-0015.

The Disclosures that Altered the Landscape

On April 27 and 28, 2026, two significant disclosures sent shockwaves through the market, resulting in a drastic drop in Erasca's stock prices. The first was a revelation of legal challenges from Revolution Medicines regarding patent infringement and trade secrets. The second was the unsettling report of adverse clinical trial data, which included the unfortunate death of a patient linked to the ERAS-0015 trials.

This catastrophe led to a market slump that erased over $2.8 billion in market capitalization. Investors were left scrambling, having been previously assured of the compound's safety and the company's position in the cancer treatment market.

Call to Action for Affected Investors

Hagens Berman is urging all investors who suffered significant losses due to the alleged securities fraud to come forward. The law firm is reaching out to collective investors for participation in the ongoing litigation, looking to hold Erasca accountable for its actions.

Those interested in participating must note that the deadline to serve as lead plaintiff in the ongoing lawsuit is August 10, 2026. Investors are encouraged to contact the firm to discuss their rights and any potential recovery avenues.

For more information, interested investors can reach out to Hagens Berman directly through their contact portal. They also highlight that whistleblowers with inside knowledge regarding Erasca's operations may help the investigation, benefiting from the SEC's Whistleblower Program.

About Hagens Berman

Hagens Berman is a globally recognized complex litigation firm dedicated to protecting the rights of investors and consumers. They pride themselves on their commitment to corporate accountability and have a history of securing over $2.9 billion in settlements for their clients. For updates and news, follow Hagens Berman on their social media platforms.

In summary, the ongoing investigation into Erasca highlights the critical importance of transparency and honesty in corporate communications, especially within the high-stakes environment of pharmaceutical developments. Stakeholder rights and safety should remain paramount as the situation unfolds.